AKT1 and B-cell chronic lymphocytic leukemia: While intermediate levels of PI3K/AKT activity are essential for the survival of CLL cells, we show that the negative regulator SHIP1 is required to balance PI3K/AKT signaling in CLL to prevent hyperactivation of BCR-downstream signaling and clonal deletion.